

|                          |                                                                                                                                                                                                                                                                    | EMLc               | ATC codes: J01DD01 |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------|
| Indication               | Other specified pneumonia                                                                                                                                                                                                                                          | ICD11 code: CA40.Y |                    |
| INN                      | Cefotaxime                                                                                                                                                                                                                                                         |                    |                    |
| Medicine type            | Chemical agent                                                                                                                                                                                                                                                     |                    |                    |
| Antibiotic groups        | <div><div>W</div>WATCH</div>                                                                                                                                                                                                                                       |                    |                    |
| List type                | Core (EML)<br>(EMLc)                                                                                                                                                                                                                                               |                    |                    |
| Additional notes         | 3rd generation cephalosporin of choice for use in hospitalized neonates.                                                                                                                                                                                           |                    |                    |
| Formulations             | Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) ; 500 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt) |                    |                    |
| EML status history       | First added in 2017 (TRS 1006)<br>Changed in 2023 (TRS 1049)                                                                                                                                                                                                       |                    |                    |
| Sex                      | All                                                                                                                                                                                                                                                                |                    |                    |
| Age                      | Also recommended for children                                                                                                                                                                                                                                      |                    |                    |
| Therapeutic alternatives | The recommendation is for this specific medicine                                                                                                                                                                                                                   |                    |                    |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .                                                                                         |                    |                    |
| Wikipedia                | <a href="#">Cefotaxime</a>                                                                                                                                                      |                    |                    |
| DrugBank                 | <a href="#">Cefotaxime</a>                                                                                                                                                      |                    |                    |

### Expert Committee recommendation

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.

### EML recommendations: Other specified pneumonia

First choice

Second choice

HOSPITAL-ACQUIRED PNEUMONIA

piperacillin + tazobactam

amoxicillin + clavulanic acid

cefotaxime

ceftriaxone

